How has Oklo's indefinite-lived research and development assets changed year-over-year?

Oklo's indefinite-lived research and development assets decreased by 0.0% year-over-year, from $27.5M to $27.5M.

Oklo OKLO Indefinite-Lived Research and Development Assets

Honeywell InternationalHON

——

Cardinal HealthCAH

——

Operating income-$51.2M-187%

Net income-$33.1M-237%

EPS (diluted)-$0.19-171%

Cash & equivalents$15.6M+233%

Total debt$2.6M+46.1%

Total equity$2.6B+880%

Total assets$2.7B+795%

Operating cash flow-$17.9M-45.9%

CapEx$32.8M+9,783%

Free cash flow-$50.7M-303%

Market cap$10.64B+186%

Enterprise value$10.63B+186%

Return on equity-8.9%—

Debt / equity0×0.0×

Current ratio59.9×+23.7×

Reported directly by Oklo in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Oklo’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Oklo's indefinite-lived research and development assets?: Oklo (OKLO) reported indefinite-lived research and development assets of $27.5M in Q1 2026.
How has Oklo's indefinite-lived research and development assets changed year-over-year?: Oklo's indefinite-lived research and development assets decreased by 0.0% year-over-year, from $27.5M to $27.5M.